|
Reference (author, year)
|
Region
|
Definition of CSU in weeks
|
Treatment
|
Number of CSU subjects undergoing IgE testing
|
Mean total IgE (kU/L) (SD)
|
Median Total IgE (kU/L) (IQR)
|
% of subjects previously on systemic corticosteroids (SC)
|
Number of antihistamine (AH) or systemic corticosteroid-free days
|
Range (kU/L)
|
|---|
|
Maurer, 2011 [68]
|
Germany
|
> 6
|
Omalizumab
|
27
|
211 (158)
|
–
|
–
|
–
|
–
|
| | | |
Placebo
|
22
|
181 (136)
|
–
|
–
|
–
|
–
|
|
Saini, 2011 [69]
|
USA and Germany
|
> 6
|
Omalizumab or Placebo
|
90
|
215 (432)
|
88.5
|
–
|
–
|
2–3510
|
|
Nam, 2012 [70]
|
Korea
|
> 6
|
Omalizumab
|
26
|
248 (275)
|
–
|
42.3
|
–
|
–
|
|
Kaplan, 2013 [71]
|
Various countries
|
> 6
|
Omalizumab or Placebo
|
335
|
159 (288)
|
78
|
57.9
|
16
|
1–3050
|
|
Labrador-Horrillo, 2013 [72]
|
Spain
|
> 6
|
Omalizumab
|
107
|
133
|
–
|
77.3
|
–
|
2–1042
|
|
Maurer, 2013 [73]
|
Various countries
|
> 6
|
Omalizumab or Placebo
|
322
|
168 (232)
|
78
|
–
|
30 (SC)
|
–
|
|
Rottem 2014 [74]
|
Israel
|
> 6
|
Omalizumab
|
43
|
151 (255)
|
–
|
88
|
–
|
–
|
|
Saini, 2015 [35]
|
Various countries
|
> 6
|
Omalizumab or Placebo
|
318
|
–
|
83
|
–
|
16 (SC)
|
1–5000
|
|
Ensina, 2016 [75]
|
Brazil
|
–
|
Omalizumab
|
27
|
159
|
–
|
–
|
–
|
0.2–774
|
|
Gomez-Vera, 2016 [25]
|
Mexico
|
> 6
|
Omalizumab
|
26
|
–
|
55.5
|
–
|
–
|
31.5–186
|
|
Wilches, 2016 [76]
|
Ecuador
|
> 6
|
Omalizumab
|
26
|
571
|
–
|
–
|
–
|
55–2500
|
|
Deza 2017 [77]
|
Spain
|
> 6
|
Omalizumab
|
47
|
–
|
116
|
–
|
–
|
42–277
|
|
Gericke, 2017 [78]
|
Germany
|
> 6
|
Omalizumab
|
56
|
205 (230)
|
–
|
–
|
–
|
–
|
|
Jorg, 2017 [79]
|
Switzerland
|
> 6
|
Omalizumab or Placebo
|
30
|
–
|
137 (37.8–311)
|
–
|
AH, SC allowed
|
–
|
|
Metz, 2017 [80]
|
Germany
|
> 6
|
Omalizumab
|
20
|
432 (1031)
|
–
|
–
|
3 (AH), 30 (SC)
|
–
|
| | | |
Placebo
|
10
|
184 (242)
|
–
|
–
|
3 (AH), 30 (SC)
|
–
|
|
Nettis, 2017 [81]
|
Italy
|
> 6
|
Omalizumab
|
290
|
235 (526)
|
120
|
73.5
|
Allowed (AH, SC)
|
0–5237
|
|
Yang, 2017 [82]
|
Taiwan
|
> 6
|
Omalizumab
|
17
|
272.6
|
–
|
23.5
|
–
|
8.9–1510
|
|
Bulur, 2018 [83]
|
Turkey
|
> 6
|
Omalizumab
|
132
|
54.4 (150)
|
65
|
62.1
|
Allowed (AH, SC)
|
7–978.9
|
|
Ertas, 2018 [84]
|
Turkey
|
> 6
|
Omalizumab
|
96
|
–
|
66.8
|
–
|
–
|
20.4–127
|
|
Ghazanfar, 2018 [85]
|
Denmark
|
> 6
|
Omalizumab
|
117
|
467 (1076)
|
–
|
–
|
Allowed (AH)
|
–
|
|
Hide, 2018 [86]
|
Japan
|
> 6
|
Omalizumab 150 mg
|
71
|
–
|
335
|
26.5
|
30
|
15–2360
|
| | | |
Omalizumab 300 mg
|
73
|
–
|
428
|
37.1
| |
20–4950
|
| | | |
Placebo
|
73
|
–
|
414
|
36.1
| |
0–5600
|
|
Türk, 2018 [87]
|
Turkey
|
> 6
|
Omalizumab
|
25
|
–
|
226
|
–
|
–
|
56–340
|
- AH antihistamine, SC systemic corticosteroids
